Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation / 전남의대학술지
Chonnam Medical Journal
;
: 6-11, 2020.
Artículo
en Inglés
| WPRIM
| ID: wpr-787280
ABSTRACT
Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Naciones Unidas
/
Receptores de Antígenos
/
Linfocitos T
/
Causas de Muerte
/
Terapia Combinada
/
Carcinogénesis
/
Tratamiento Basado en Trasplante de Células y Tejidos
/
Sistema Inmunológico
/
Ligandos
/
Reacciones Antígeno-Anticuerpo
Límite:
Humanos
Idioma:
Inglés
Revista:
Chonnam Medical Journal
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS